
DATA SHEET

NAME OF MEDICINE

Juvéderm ULTRA[®] XC 24mg/mL injectable gel implant

Presentation

Juvéderm ULTRA[®] XC injectable gel implant is a sterile pyrogen-free physiological solution of cross-linked hyaluronic acid which is not of animal origin. The gel is presented in a graduated pre-filled and disposable syringe.

Uses

Actions

Juvéderm consists of hyaluronic acid (HA) a polysaccharide naturally present in the body at different concentrations, especially in the skin, muscular system and skeleton. The concentration of HA in the skin naturally decreases with age. The result is a decrease in the skin's elasticity and ability to hold water. This renders the dermis less voluminous and increases the tendency of the skin to form wrinkles. By chemically cross-linking molecules of HA more stable macromolecules are formed which have the same biocompatibility as native HA. Because HA cannot penetrate into the skin when applied topically HA derivatives are injected into the dermal tissue to provide a space-occupying viscoelastic matrix of the connective tissue. The development of solutions based on cross-linked hyaluronic acid made it possible to improve the *in situ* remanence, but these products can be painful during injection. Addition of 0.3% lidocaine hydrochloride intends to limit pain directly linked to the injection, without using other techniques of anaesthesia.

Indications

Juvéderm ULTRA[®] XC injectable gel implant is indicated for use in filling of medium size depressions of the skin via mid dermis injection and to create definition and pouting of lips.

Dosage and Administration

Juvéderm ULTRA[®] XC contains 24mg/mL cross-linked hyaluronic acid in a physiological buffer.

Juvéderm ULTRA[®] XC is designed to be injected into the dermis or the mucous membrane of the lips by a practitioner. The technique used for this is essential in the success of treatment and therefore *Juvéderm ULTRA*[®] XC must be used by doctors who have received specific training in the injection technique for filling wrinkles.

Before starting treatment patients should be informed of the indications for the device, its contra-indications, incompatibilities and potential undesirable effects.

The area to be treated should be disinfected thoroughly prior to the injection.

Remove tip cap by pulling it straight off the syringe. Then firmly push the needle provided in the box into the syringe, screwing it gently clockwise. Twist once more until it is fully locked. Next, remove the protective cap by holding the body of the syringe in one hand, the protective cap in the other and pulling the two hands in opposite directions. Failure to comply with these precautions could cause a disengagement of the needle and/or product leakage at luer-lock level. Inject slowly into the mid dermis using the linear tracking injection technique using the 30G1/2" needle provided. The amount injected will depend on the areas to be corrected.

It is important to massage the area treated after the injection in order to ensure that the substance has been uniformly distributed.

Contraindications

- Do not inject *Juvéderm ULTRA[®] XC* injectable gel into the eye lids. The application of *Juvéderm ULTRA[®] XC* in the bags under the eyes is reserved to specialists specifically trained in this technique and having a sound knowledge of the physiology for this particular area.
- Do not overcorrect.
- *Juvéderm ULTRA[®] XC* must not be used in patients suffering from epilepsy.
- *Juvéderm ULTRA[®] XC* injectable gel must not be used in patients who are known to be hypersensitive to hyaluronic acid.
- *Juvéderm ULTRA[®] XC* injectable gel must not be used in patients who are known to be hypersensitive to lidocaine or to amide-type local anaesthetics.
- *Juvéderm ULTRA[®] XC* injectable gel must not be in patients suffering from porphyria.
- *Juvéderm ULTRA[®] XC* injectable gel must not be used simultaneously with laser therapy, chemical peeling or dermabrasion.

Warnings and Precautions

Juvéderm ULTRA[®] XC injectable gel is not indicated for injections other than intra-dermal injections.

- *Juvéderm ULTRA[®] XC* must not be used in patients who tend to develop hypertrophic scarring.
- There is no available clinical data (efficiency, tolerance) about injection of *Juvéderm ULTRA[®] XC* injectable gel into an area which has already been treated with another filling product.
- There is no available clinical data (efficiency, tolerance) about injection of *Juvéderm ULTRA[®] XC injectable gel* in patients with a past history or a declared autoimmune disease. The practitioner should then decide to inject case by case, according to the nature of the disease and the associated treatment and ensure a particular follow-up of these patients.
- There is no available clinical data (efficiency, tolerance) about injection of *Juvéderm ULTRA[®] XC injectable gel* in patients having a history of severe multiple allergies or anaphylactic shock.
- *Juvéderm ULTRA[®] XC* is not recommended in patients showing a history of streptococcal disease and in the event of rheumatic fever with heart complications.
- The safety of *Juvéderm ULTRA[®] XC* injectable gel for use during pregnancy, in breastfeeding females or in patients under 18 years has not been established.

- Patients should be recommended not to apply make-up for 12 hours after the injection and to avoid prolonged exposure to sunlight, UV light, freezing temperatures or using saunas or Turkish baths for the two weeks after the injection.
- Athletes should be made aware that *Juvéderm ULTRA PLUS[®]XC* injectable gel contains lidocaine which may produce a positive result in anti-doping tests.
- If the needle is blocked, do not increase the pressure on the plunger rod but stop the injection and replace the needle.
- Do not inject *Juvéderm ULTRA[®]XC* injectable gel into the blood vessels (intravascular).
- *Juvéderm ULTRA[®]XC* injectable gel must not be used in areas presenting cutaneous inflammatory and/or infectious processes (e.g. acne).
- For surface peels, it is recommended, not to inject *Juvéderm ULTRA[®]XC* injectable gel if the inflammatory reaction generated is significant.
- Confirm the integrity of the sterility protector before use.
- Do not re-use.
- Do not re-sterilise.
- The needle used must be disposed of in a special receptacle.

INCOMPATIBILITIES

Hyaluronic acid is known to be incompatible with quaternary ammonium salts such as benzalkonium chloride. *Juvéderm ULTRA[®]XC* injectable gel should never therefore be placed in contact with these substances or with medical-surgical instrumentation which has been treated with this type of substance.

Adverse Effects

Practitioners must inform the patient that there are potential side effects associated with implantation of this device, which may occur immediately or may be delayed. These include (non-exhaustive list):

- Inflammatory reactions (e.g. redness, oedema, erythema) which may be associated with itching, pain on pressure, occurring after the injection. These reactions may last for a week.
- Induration or nodules at the injection site.
- Discolouration of the injection site.
- Poor effect or weak filling effect.
- Cases of glabellar necrosis, abscess formation, granuloma and hypersensitivity have all been reported in the literature following hyaluronic acid injection. It is therefore important to take such possible complications into account.

Patients must report inflammatory reactions which persist for more than one week or any other secondary effect which develops, to their practitioner as soon as possible. The practitioner should treat these as appropriate. Any other undesirable side effects associated with injection of *Juvéderm ULTRA[®]XC* injectable gel must be reported to the distributor.

Pharmaceutical Precautions

Juvéderm ULTRA[®]XC injectable gel must be used prior to the expiration date printed on the package.

Juvéderm ULTRA[®]XC injectable gel has a shelf life of 24 months when stored between 2°C and 25°C.

Juvéderm ULTRA[®]XC injectable gel contains trace amounts (<2ppm) of the cross linking agent butanediol diglycidyl ether (BDDE).

Medicine Classification

Prescription Medicine

Package Quantities

Each box contains 2 syringes of *Juvéderm ULTRA[®]XC* injectable gel, 4 single-use 30G1/2" disposable sterile needles, reserved for injection of *Juvéderm ULTRA[®]XC* injectable gel.

A product leaflet and a set of labels showing the batch number, one of which should be attached to the patient's file and the other should be given to the patient in order to ensure traceability.

Name and Address

Allergan New Zealand Limited
Cnr Manu Tapu Drive & Joseph Hammond Place,
Auckland International Airport,
Mangere
Auckland 1
New Zealand
Toll free telephone: 0800 659 912

Date of Preparation

December 2009